Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer

Merck has been in the FDA’s crosshairs over accelerated approvals for PD-(L)1 inhibitor Keytruda that have whiffed in confirmatory studies. One of those speedy nods, a pairing with TKI inhibitor Lenvima from Eisai in endometrial cancer, has now scored a much-needed OS win to back up its case.